Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
European Journal of Cancer2019Vol. 121, pp. 123–129
Citations Over TimeTop 1% of 2019 papers
Khalil Saleh, Amaury Daste, Nicolas Martin, Elvire Pons‐Tostivint, Anne Aupérin, Ruth Gabriela Herrera Gómez, N. Baste-Rotllan, François Bidault, J. Guigay, Christophe Le Tourneau, Esma Saâda-Bouzid, Caroline Even
Related Papers
- → Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma(2014)60 cited
- → The Role of Akt in Acquired Cetuximab Resistant Head and Neck Squamous Cell Carcinoma: An In Vitro Study on a Novel Combination Strategy(2021)18 cited
- → Cetuximab sensitivity of head and neck squamous cell carcinoma xenografts is associated with treatment‐induced reduction in EGFR, pEGFR, and pSrc(2016)8 cited
- → Abstract 4108: Targeting IL-6 signaling overcomes cetuximab resistance in head and neck squamous cell carcinoma(2017)1 cited
- → Data from Combination of Anti-HER3 Antibody MM-121/SAR256212 and Cetuximab Inhibits Tumor Growth in Preclinical Models of Head and Neck Squamous Cell Carcinoma(2023)